# Edaravone Dexborneol for Treatment of Hypertensive Intracerebral Hemorrhage

Study · id `cardio:ct-nct04714177` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04714177](<https://clinicaltrials.gov/study/NCT04714177>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04714177

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 390 participants.

## Technical summary

Registry record NCT04714177. Randomized; quadruple masking; primary purpose treatment. Start 2021-03-01 (anticipated); primary completion 2023-03-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 390 participants (planned count; ClinicalTrials.gov record NCT04714177, source copy `cardio:ctgov-nct04714177-2021-01-19`, retrieved 2026-10-31)
- Planned start: 2021-03-01 (anticipated) (ClinicalTrials.gov record NCT04714177, source copy `cardio:ctgov-nct04714177-2021-01-19`, retrieved 2026-10-31)
- Primary completion: 2023-03-01 (anticipated) (ClinicalTrials.gov record NCT04714177, source copy `cardio:ctgov-nct04714177-2021-01-19`, retrieved 2026-10-31)
- Completion: 2023-09-01 (anticipated) (ClinicalTrials.gov record NCT04714177, source copy `cardio:ctgov-nct04714177-2021-01-19`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04714177-2021-01-19`, retrieved 2026-10-31)

## The registry's words

- Brief title: Edaravone Dexborneol for Treatment of Hypertensive Intracerebral Hemorrhage
- Acronym: ED-ICH
- Condition: Intracerebral Hemorrhage
- Intervention (Drug): Edaravone Dexborneol
- Intervention (Drug): Placebo
- Lead sponsor: First Affiliated Hospital, Sun Yat-Sen University
- Lead sponsor class: OTHER
- Collaborator: Jiangsu Simcere Pharmaceutical Co., Ltd.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Bleeding in the brain (intracerebral hemorrhage) (`cardio:intracerebral-hemorrhage`)
- Registry lists this organization as the lead sponsor: First Affiliated Hospital, Sun Yat-Sen University (`cardio:org-first-affiliated-hospital-sun-yat-sen-university`)
- Registry lists this organization as a collaborator: Jiangsu Simcere Pharmaceutical Co., Ltd. (`cardio:org-jiangsu-simcere-pharmaceutical-co-ltd`)

## Provenance

Content hash: fa082262bf57efc23d79056342f1b16140a7c598d13b12ca97bcec6b06491798
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
